

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S0521-APL,Low/Int Risk, Maint vs Obs	1 N 1 ATRA + ARA-C + Daunorubicin	550	105	0	0	0	0	0		
			105	0	0	0	0	0		
	2 Y 2 Consolidation		92	0	0	0	0	0		
			92	0	0	0	0	0		
	3 Y 3 ATRA + 6MP + MTX	440	41	1	0	0	0	0		
	4 Observation		27	0	0	0	0	0		
			68	1	0	0	0	0		
	4 N 5 Gemtuzumab Ozogamicin		1	0	0	0	0	0		
			1	0	0	0	0	0		
	S0535-APL,High Risk, ATRA/arsenic/GO	1 Y 1 ATRA + G.O. + Arsenic	77	54	19	12	5	3	0	130
			54	19	12	5	3	0		
2 Y 2 Consolidation			39	10	6	4	2	0	130	52
			39	10	6	4	2	0		
3 Y 3 ATRA + 6-MP + MTX			24	4	2	2	2	0	130	52
			24	4	2	2	2	0		
S0703-AML, AGE 60+, AZACITIDINE G.O.	3 Y 3 Azacitidine	139	24	3	3	2	1	0	163	53
			24	3	3	2	1	0		

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S0703-AML, age 60+, Azacitidine G.O.	1 Y 1 Hydroxyurea/Azacitidine/G.O.	153	132	42	26	16	11	3	163	53
			132	42	26	16	11	3		
	2 Y 2 Azacitidine/G.O.	139	33	8	5	3	2	0	163	53
			33	8	5	3	2	0		
S0805-PH+ ALL, DASATINIB/CVAD +/- BMT	4 Y 4 Dasatinib		4	3	3	1	1	1	93	39
			4	3	3	1	1	1		
S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT	1 Y 1 Induction/Consolidation	94	23	20	12	8	2	0	93	39
			23	20	12	8	2	0		
	3 Y 3 Allo stem cell transplant	37	8	7	4	3	3	1	93	39
			8	7	4	3	3	1		
S0910-Rel ph-, B-ALL, Epratuzumab+Cy+Clo	1 Y 1 ARA-C+Clofarabine+Epratuzumab	35	25	21	13	8	2	0	119	35
			25	21	13	8	2	0		
S0919-Rel AML: Pravastatin+Ida+Ara-C	1 Y 1 Pravastatin+Idarubicin+Ara-C	55	25	14	8	4	0	0	113	36
			25	14	8	4	0	0		
	2 Y 2 Pravastatin+Idarubicin+Ara-C		7	4	2	2	0	0	113	36
			7	4	2	2	0	0		

LEUK ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
C10403-ALL <40 yrs-Ped,Chemo. Regimen	1 Y 1 Sequential Chemotherapy	300	65	25	13	7	3	1	142	59
			65	25	13	7	3	1		
C10404-CLL, Flu/Rituxan combinations	1 Y 1 Flu/Rituximab	300	9	6	2	2	1	0	121	55
	2 Flu/Rituximab/Lenalidomide		5	2	1	1	0	0		
	3 Flu/Cy/Rituximab		12	6	3	2	1	0		
			26	14	6	5	2	0		
E1908-Tx of PCL Leuk w/Alemtuz, Ritux	1 E Total Registrations		1	1	1	0	0	0	45	22
			1	1	1	0	0	0		
E2905-MDS, Len vs Len + Epo	1 E Total Registrations		21	9	4	2	2	1	148	83
			21	9	4	2	2	1		

LEUK Open Studies with No Registrations

Study	Registration/Phase	OPENDT
S0805 Ph+ ALL, Dasatinib/CVAD +/- BMT	2 Maintenance	01-Sep-09

1 row selected.

no rows selected